News

October 22, 2019

Phase 2 Trial Testing Darinaparsin Completes Enrollment of Asian Patients with Relapsed or Refractory PTCL

News

A Phase 2 clinical trial assessing Solasia Pharma’s lead candidate darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) in Asian patients has reached its target enrollment, ... Read more

October 18, 2019

HIV-positive, Non-Hodgkin’s Lymphoma Patients Should Receive Chemotherapy Along with Antiretrovirals Therapy, Retrospective Study Says

News

People with non-Hodgkin’s lymphoma who are HIV-positive and have not received antiretroviral therapy — a treatment that stops HIV from replicating — have similar outcomes on standard R-CHOP chemotherapy, compared ... Read more

October 17, 2019

HealthWell Foundation Offers Treatment Payment Assistance for Mantle Cell Lymphoma

News

To allow patients to focus on treatment and not cost, the HealthWell Foundation is offering copayment and insurance premium assistance to people with mantle cell lymphoma (MCL) who are on ... Read more

October 15, 2019

Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show

News

IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials ... Read more

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, ... Read more

October 8, 2019

Consolidation Radiotherapy Important After Treatment for Early Hodgkin’s Lymphoma, Clinical Study Shows

News

Radiotherapy following chemotherapy reduces the risk of cancer progression in people with early-stage favorable Hodgkin’s lymphoma, regardless of an individual’s response to chemotherapy, results of a Phase 3 study show. ... Read more

October 4, 2019October 25, 2019

CLR 131 Works to Halt Cancer Growth and Lower Tumor Volume in DLBCL, Early Phase 2 Data Show

News

Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), interim data of a Phase 2 trial ... Read more

October 3, 2019

Adcetris Most Effective in Chemo-sensitive Patients, or as Consolidation Therapy After Stem Cell Transplant, Study Finds

News

Treatment with Adcetris (brentuximab vedotin) is most effective in people with relapsed or refractory Hodgkin’s lymphoma who have chemotherapy-sensitive disease, and when used as consolidation therapy immediately after stem cell ... Read more

October 1, 2019October 1, 2019

Radiation Prior to CAR T-cell Therapy in Non-Hodgkin’s Lymphoma May Ease Side Effects, Study Suggests

News

Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the ... Read more

September 27, 2019October 16, 2019

Compass Self Storage Raises $100K for the Leukemia & Lymphoma Society’s Children’s Initiative

News

Compass Self Storage has raised more than $100,000 this year for the Leukemia & Lymphoma Society (LLS), particularly for its children’s initiative. The $101,618 raised brings to more than $500,000 ... Read more